STOCK TITAN

Sight Sciences, Inc. - $SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: $SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sight Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sight Sciences's position in the market.

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported preliminary financial highlights for Q4 and full year 2023, with total revenue expected to be $18.6-18.8 million for Q4, a 9% decrease, and $80.9-81.1 million for the full year, a 14% increase. Cash and cash equivalents as of Dec 31, 2023, were approximately $138 million. The company's Q4 and full year 2023 financial results are preliminary and subject to audit, with complete results expected in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) supports the decision by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery, ensuring continued access to comprehensive outflow procedure enabled by OMNI Surgical System technology for glaucoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
-
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the publication of the six-month primary results from the SAHARA randomized controlled trial, demonstrating the superior efficacy of interventional eyelid procedures enabled by TearCare technology over Restasis in addressing the underlying causes of evaporative dry eye.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the acceptance for publication of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI Surgical System technology. The trial demonstrated sustained and clinically significant intraocular pressure reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months. The data further supports the need for continued access to OMNI technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
-
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported Q3 2023 revenue of $20.0 million, a 7% increase YoY. The company withdrew its full year 2023 guidance due to uncertainties caused by a recent LCD that would limit Medicare patient access to a key procedure. The company also appointed a new Chief Commercial Officer and implemented cost-saving initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
-
Rhea-AI Summary
Sight Sciences, Inc. will report financial results for Q3 2023 on November 7th. The company's management will discuss the results during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
Rhea-AI Summary
Sight Sciences announces TearCare SAHARA Six Month RCT Results reception
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
-
Rhea-AI Summary
Sight Sciences announces positive results from the SAHARA trial, demonstrating the superiority of TearCare technology over Restasis eyedrops for the treatment of dry eye disease. TearCare showed statistically significant improvements in tear break up time and other objective signs of dry eye compared to Restasis. Both treatments delivered comparable improvements in patient-reported outcomes. TearCare offers an efficacious and durable interventional dry eye treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary
Sight Sciences announces results of a large-scale study comparing MIGS technologies for glaucoma patients. TCOR procedure using OMNI Surgical System shows significant reduction in IOP and medication usage. OMNI technology delivers clinically meaningful and durable results. Independent data from the IRIS Registry informs surgeons' decision-making. Sight Sciences aims to elevate the standard of care with its technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
Rhea-AI Summary
Sight Sciences updates revenue guidance for Q3 2023 to $19.0M-$20.0M, expects decrease in new account additions and utilization due to proposed LCDs. Revenue from Dry Eye segment to be slightly down sequentially. Full year 2023 revenue guidance updated to $80.0M-$82.0M, representing 12%-15% growth compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.62%
Tags
none
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

SGHT Stock Data

296.49M
28.86M
21.78%
51.34%
2.6%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MENLO PARK

About SGHT

sight sciences, inc. is a medical devices company based out of menlo park, california, united states.